Media Newsroom of
ARTIDIS AG
At ARTIDIS AG, we are committed to radically improving health outcomes by harnessing the power of nanotechnology and innovation. We enable rapid diagnosis and treatment optimization tailored to individual patient needs and desired outcomes.
ARTIDIS Gains Strong Momentum in 2019, Raising CHF 8.8 Million in Seed Financing
The funding will be used to advance the company’s healthtech platform into a large multi-centre clinical study together with the University Hospital Tuebingen (Germany), University Hospital Barcelona (Spain), and Texas Medical Center (Houston, US). The study aims to further validate…
ARTIDIS Joins the TMC Accelerator Device Cohort to Ensure That Its Cancer Diagnostic and Therapeutic Optimization Innovation Gains Early Access to the US Market
ARTIDIS is one of the 16 startups selected worldwide from more than 140 competing healthcare companies for the 9th TMC accelerator medical device cohort. After completing the TMC Accelerator Program that culminated with a Demo Day presentation on Nov. 7, 2019,…